Nektar Therapeutics Stock Net Asset
| NKTR Stock | USD 1.10 0.14 14.58% |
Nektar Therapeutics fundamentals help investors to digest information that contributes to Nektar Therapeutics' financial success or failures. It also enables traders to predict the movement of Nektar Stock. The fundamental analysis module provides a way to measure Nektar Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Nektar Therapeutics stock.
Nektar | Net Asset |
Nektar Therapeutics Company Net Asset Analysis
Nektar Therapeutics' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Nektar Therapeutics Net Asset | 398.03 M |
Most of Nektar Therapeutics' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Nektar Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Nektar Net Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Nektar Therapeutics is extremely important. It helps to project a fair market value of Nektar Stock properly, considering its historical fundamentals such as Net Asset. Since Nektar Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Nektar Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Nektar Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Nektar Total Assets
Total Assets |
|
Based on the recorded statements, Nektar Therapeutics has a Net Asset of 398.03 M. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Nektar Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nektar Therapeutics' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Nektar Therapeutics could also be used in its relative valuation, which is a method of valuing Nektar Therapeutics by comparing valuation metrics of similar companies.Nektar Therapeutics is currently under evaluation in net asset category among its peers.
Nektar Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Nektar Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Nektar Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Nektar Therapeutics' value.| Shares | State Street Corp | 2024-09-30 | 3.3 M | Renaissance Technologies Corp | 2024-09-30 | 3.3 M | Jacobs Levy Equity Management, Inc. | 2024-09-30 | 2.8 M | Monaco Asset Management | 2024-09-30 | 2 M | Goldman Sachs Group Inc | 2024-09-30 | 1.8 M | Woodline Partners Lp | 2024-09-30 | 1.7 M | Shay Capital Llc | 2024-09-30 | 1.6 M | Two Sigma Advisers, Llc | 2024-09-30 | 1.5 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1.5 M | Blackrock Inc | 2024-09-30 | 16 M | Deep Track Capital, Lp | 2024-09-30 | 15.9 M |
Nektar Fundamentals
| Return On Equity | -1.62 | ||||
| Return On Asset | -0.23 | ||||
| Profit Margin | (1.81) % | ||||
| Operating Margin | (1.42) % | ||||
| Current Valuation | 66.67 M | ||||
| Shares Outstanding | 184.46 M | ||||
| Shares Owned By Insiders | 1.29 % | ||||
| Shares Owned By Institutions | 76.57 % | ||||
| Number Of Shares Shorted | 4.4 M | ||||
| Price To Earning | 8.02 X | ||||
| Price To Book | 4.15 X | ||||
| Price To Sales | 2.18 X | ||||
| Revenue | 90.12 M | ||||
| Gross Profit | 70.42 M | ||||
| EBITDA | (243.11 M) | ||||
| Net Income | (276.06 M) | ||||
| Cash And Equivalents | 546.39 M | ||||
| Cash Per Share | 2.91 X | ||||
| Total Debt | 117.78 M | ||||
| Debt To Equity | 0.33 % | ||||
| Current Ratio | 7.14 X | ||||
| Book Value Per Share | 0.27 X | ||||
| Cash Flow From Operations | (192.61 M) | ||||
| Short Ratio | 1.92 X | ||||
| Earnings Per Share | (0.84) X | ||||
| Price To Earnings To Growth | 3.22 X | ||||
| Target Price | 4.7 | ||||
| Number Of Employees | 137 | ||||
| Beta | 0.61 | ||||
| Market Capitalization | 202.9 M | ||||
| Total Asset | 398.03 M | ||||
| Retained Earnings | (3.48 B) | ||||
| Working Capital | 279.43 M | ||||
| Current Asset | 350.05 M | ||||
| Current Liabilities | 61.25 M | ||||
| Net Asset | 398.03 M |
About Nektar Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nektar Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nektar Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nektar Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Nektar Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Nektar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nektar Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Nektar Stock
| 0.87 | DNLI | Denali Therapeutics | PairCorr |
| 0.63 | EVOK | Evoke Pharma | PairCorr |
| 0.82 | FOLD | Amicus Therapeutics | PairCorr |
| 0.87 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
Moving against Nektar Stock
| 0.77 | LFCR | Lifecore Biomedical | PairCorr |
| 0.66 | BMY | Bristol Myers Squibb | PairCorr |
| 0.48 | GILD | Gilead Sciences | PairCorr |
| 0.4 | IMCC | Im Cannabis Corp | PairCorr |
The ability to find closely correlated positions to Nektar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Nektar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Nektar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Nektar Therapeutics to buy it.
The correlation of Nektar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Nektar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Nektar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Nektar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Nektar Stock Analysis
When running Nektar Therapeutics' price analysis, check to measure Nektar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nektar Therapeutics is operating at the current time. Most of Nektar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nektar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nektar Therapeutics' price. Additionally, you may evaluate how the addition of Nektar Therapeutics to your portfolios can decrease your overall portfolio volatility.